发布求助
文献互助 智能选刊 最新文献

Pharmaceutical patent analyst最新文献

筛选
英文 中文
Potential of novel self-assembled functionalized carbon nanotubes for selective tumor targeting. 新型自组装功能化碳纳米管选择性靶向肿瘤的潜力。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-05-01 Epub Date: 2022-07-21 DOI: 10.4155/ppa-2022-0001
Chetan D Sabanis, Bharathi R Kannan, Ramesh Joga, Simran, Sandeep Kumar, Neeraj Kumar
{"title":"Potential of novel self-assembled functionalized carbon nanotubes for selective tumor targeting.","authors":"Chetan D Sabanis,&nbsp;Bharathi R Kannan,&nbsp;Ramesh Joga,&nbsp;Simran,&nbsp;Sandeep Kumar,&nbsp;Neeraj Kumar","doi":"10.4155/ppa-2022-0001","DOIUrl":"https://doi.org/10.4155/ppa-2022-0001","url":null,"abstract":"<p><p>Conventional cancer therapies are associated with toxicity toward healthy cells, which need to be addressed by novel therapeutic approaches. US2021/0230592 patent application discloses a carbon nanotube-based approach for tumor targeting, wherein a self-assembling single-wall nanotube complex has been developed and functionalized to deliver a molecule to a cancerous cell. The radiolabeled nanotubes exhibited markedly reduced toxicity as they did not depict any 'over toxicity' up to radioactivity value of 1350 nCi. The single-wall carbon nanotube conjugates were covalently connected to several chelators, therapeutic or diagnostic radionuclides, and showed promising results in the effective cancer management. Besides, this invention with further modifications paves an ideal pathway to researchers in effective diagnosis and treatment of cancer.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"11 3","pages":"111-117"},"PeriodicalIF":1.3,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40541575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Baicalein: promising therapeutic applications with special reference to published patents. 黄芩苷:有前景的治疗应用，特别参考已发表的专利。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-03-29 DOI: 10.4155/ppa-2021-0027
Shubhangi Gupta, H. Buttar, Ginpreet Kaur, H. Tuli
{"title":"Baicalein: promising therapeutic applications with special reference to published patents.","authors":"Shubhangi Gupta, H. Buttar, Ginpreet Kaur, H. Tuli","doi":"10.4155/ppa-2021-0027","DOIUrl":"https://doi.org/10.4155/ppa-2021-0027","url":null,"abstract":"Baicalein is a medicinally important flavonoid present in Scutellaria baicalensis, which has numerous biological benefits like anti-oxidant, anti-inflammatory, antihepatotoxicity, anticancer properties, etc. Recent studies have revealed that baicalein is an efficient antihepatoma agent and has the strongest antiproliferative effect toward cancerous bladder cell lines, and suppression of cell cycle progression in prostate cancer cells. This natural substance has a high commercial value because it strengthens the heart and cerebral vessels and protects the nervous system and also reduces diabetes and diabetic complications. In addition, baicalein is known to decrease inflammatory markers such as IL-1β, IL-6 and TNF-α. In this review, we have attempted to compile the list of recent therapeutic patents of baicalein used for treating different disorders.","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2022-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42953257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Small-molecule inhibitors of Slack potassium channels as potential therapeutics for childhood epilepsies. 松弛钾通道小分子抑制剂作为儿童癫痫的潜在治疗药物。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-03-01 DOI: 10.4155/ppa-2022-0002
Alshaima'a M Qunies, Kyle A Emmitte
{"title":"Small-molecule inhibitors of Slack potassium channels as potential therapeutics for childhood epilepsies.","authors":"Alshaima'a M Qunies,&nbsp;Kyle A Emmitte","doi":"10.4155/ppa-2022-0002","DOIUrl":"https://doi.org/10.4155/ppa-2022-0002","url":null,"abstract":"Slack channels are sodium-activated potassium channels that are encoded by the KCNT1 gene. Several KCNT1 gain of function mutations have been linked to malignant migrating partial seizures of infancy. Quinidine is an anti-arrhythmic drug that functions as a moderately potent inhibitor of Slack channels; however, quinidine use is limited by its poor selectivity, safety and pharmacokinetic profile. Slack channels represent an interesting target for developing novel therapeutics for the treatment of malignant migrating partial seizures of infancy and other childhood epilepsies; thus, ongoing efforts are directed toward the discovery of small-molecules that inhibit Slack currents. This review summarizes patent applications published in 2020-2021 that describe the discovery of novel small-molecule Slack inhibitors.","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"11 2","pages":"45-56"},"PeriodicalIF":1.3,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260495/pdf/ppa-11-45.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10810199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Patent highlights August-September 2021. 专利亮点2021年8月至9月。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-01-01 Epub Date: 2022-02-03 DOI: 10.4155/ppa-2021-0025
Hermann Am Mucke
{"title":"Patent highlights August-September 2021.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2021-0025","DOIUrl":"https://doi.org/10.4155/ppa-2021-0025","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"11 1","pages":"1-8"},"PeriodicalIF":1.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39758418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug repurposing of adapalene for melanoma treatment. 阿达帕林用于黑色素瘤治疗的药物再利用。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-01-01 Epub Date: 2022-02-16 DOI: 10.4155/ppa-2021-0021
Maricruz Anaya-Ruiz, Martin Perez-Santos
{"title":"Drug repurposing of adapalene for melanoma treatment.","authors":"Maricruz Anaya-Ruiz,&nbsp;Martin Perez-Santos","doi":"10.4155/ppa-2021-0021","DOIUrl":"https://doi.org/10.4155/ppa-2021-0021","url":null,"abstract":"<p><p>Cancer drug repurposing is an attractive approach that leads to savings in time and investment. Adapalene, the first medical application of which was for the treatment of acne, has been described as a repurposing drug for the treatment of various types of cancer. Patent application CN111329851 describes the use of adapalene for the treatment of melanoma, by assays carried out on melanoma cell lines. Adapalene demonstrated antiproliferative activity in melanoma cell lines via S-phase arrest-dependent apoptosis mediated by DNA damage through an increase in the expression of p-ATM and p-chk2 and a decrease in the expression of p-BRCA1 and Rad51. Even though no evidence on efficacy and efficiency is shown in preclinical and clinical studies, CN111329851 patent shows that adapalene may be a repurposing drug for the treatment of melanoma.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"11 1","pages":"9-14"},"PeriodicalIF":1.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39633611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Multicomponent crystal compromising dasatinib and selected co-crystals formers: a patent evaluation of EP2861589B1. 多组分晶体损害达沙替尼和选择的共晶体形成:EP2861589B1的专利评估。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-01-01 Epub Date: 2022-02-17 DOI: 10.4155/ppa-2021-0024
Ritu Rathi, Inderbir Singh
{"title":"Multicomponent crystal compromising dasatinib and selected co-crystals formers: a patent evaluation of EP2861589B1.","authors":"Ritu Rathi,&nbsp;Inderbir Singh","doi":"10.4155/ppa-2021-0024","DOIUrl":"https://doi.org/10.4155/ppa-2021-0024","url":null,"abstract":"<p><p>Cocrystallization has gained significant prominence in pharmaceutical product development because of the enhancement of physical, chemical and pharmacological properties of active pharmaceutical ingredients, such as stability, solubility, dissolution rate, taste, hygroscopicity, mechanical property, bioavailability, permeability and therapeutic activity. Traditionally, co-crystals can be prepared by a grinding, solvent evaporation and slurry method. However, sophisticated methods such as spa drying, hot-melt extrusion, supercritical fluid and laser irradiation are also reported to be used for producing co-crystals. The selected patent describes the development of multicomponent crystals of dasatinib, with an aim to enhance the aqueous solubility of a selected drug. However issues surrounding the toxicity, stability, large scale manufacture, <i>in vivo</i> performance in human beings and regulations require adequate addressal prior to exploring the commercial viability of pharmaceutical co-crystals.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"11 1","pages":"15-21"},"PeriodicalIF":1.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39790790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Small-molecule inhibitor PD-1/PD-L1 interaction for colorectal cancer treatment. 用于结直肠癌治疗的小分子抑制剂 PD-1/PD-L1 相互作用。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2021-12-08 DOI: 10.4155/ppa-2021-0016
Maricruz Anaya-Ruiz, Martin Perez-Santos
{"title":"Small-molecule inhibitor PD-1/PD-L1 interaction for colorectal cancer treatment.","authors":"Maricruz Anaya-Ruiz, Martin Perez-Santos","doi":"10.4155/ppa-2021-0016","DOIUrl":"10.4155/ppa-2021-0016","url":null,"abstract":"<p><p>Inhibition of the PD-1/PD-L1 pathway is a target for the development of new therapies. US10710986 patent describes a small molecule that targets PDL-1/PD-1 interactions and triggers antitumor activity against colorectal cancer. However, it does not describe biological assays that allow us to suppose that this small molecule may be active in other types of cancer. So far, there are no reports of clinical trials to evaluate the safety, toxicity and efficacy, but it will be of great interest to analyze in the future if this compound surpasses the action of therapy in cancer.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2021-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39700288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent highlights June-July 2021. 专利要点 2021 年 6 月至 7 月。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2021-11-01 Epub Date: 2021-11-10 DOI: 10.4155/ppa-2021-0022
Hermann Am Mucke
{"title":"Patent highlights June-July 2021.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2021-0022","DOIUrl":"10.4155/ppa-2021-0022","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"10 6","pages":"237-244"},"PeriodicalIF":1.8,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39692971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent patents and a market overview on green or bio-based solvents for chromatographic analysis: a review. 用于色谱分析的绿色或生物基溶剂的最新专利和市场概述：综述。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2021-11-01 Epub Date: 2021-11-10 DOI: 10.4155/ppa-2021-0015
Abdul Muheem, Mohammed Asadullah Jahangir, Sanjula Baboota, Javed Ali
{"title":"Recent patents and a market overview on green or bio-based solvents for chromatographic analysis: a review.","authors":"Abdul Muheem, Mohammed Asadullah Jahangir, Sanjula Baboota, Javed Ali","doi":"10.4155/ppa-2021-0015","DOIUrl":"10.4155/ppa-2021-0015","url":null,"abstract":"<p><p>Green solvents (GS) in chromatography originate from green chemistry. Therefore, using GSs in liquid chromatographic analysis to separate drugs and chemicals is an emerging approach to reduce hazardous chemicals in nature. The Orbit Intelligence database was used to conduct a strategic patent search for peer-reviewed patents on GSs as a mobile phase for chromatographic analysis. This article reported numerous approaches for encouraging GSs such as ethanol, butanol, esters, polyethylene glycol, supercritical fluids and nonionic surfactants to analyze drugs or compounds. The main aim of this article is to explore the patented GSs for chromatographic analysis and forecasting of the GSs that encourage industries to shift from hazardous to GSs.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"10 6","pages":"227-235"},"PeriodicalIF":1.3,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39603806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent highlights April-May 2021. 专利亮点2021年4-5月。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2021-09-06 DOI: 10.4155/ppa-2021-0011
H. Mucke
{"title":"Patent highlights April-May 2021.","authors":"H. Mucke","doi":"10.4155/ppa-2021-0011","DOIUrl":"https://doi.org/10.4155/ppa-2021-0011","url":null,"abstract":"A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"1 1","pages":""},"PeriodicalIF":1.3,"publicationDate":"2021-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41578563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信